The nation of Zimbabwe has turned down a significant American health deal worth $367m (272 million pounds) spanning five years because of the United States' demand for confidential biological samples.
This move came to light after a internal memorandum dated December was leaked, which showed Head of State Emmerson Mnangagwa deemed the deal was "unbalanced".
A government spokesperson has since explained that the US was demanding access to genetic material for research and profit but refused to share the benefits from future vaccines.
"We are forced to start the challenging and unfortunate process of winding down our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the US had furnished over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has appealed for continued dialogue to find a agreement acceptable to all parties so the nation's vital HIV treatment initiative can continue.
Broader Background
Zimbabwe's decision comes after a similar case in Kenya, where a court suspended a similar deal with the US following legal challenges were filed about the safety of citizens' medical information.
Since resuming the presidency last year, US President Donald Trump has reduced foreign aid and closed the US Agency for International Development (USAID).
USAID had managed aid for the US government, but Trump claimed its spending was "wasteful" and his government was pursuing direct bilateral deals to boost openness and responsibility.
As per reports, 16 African countries have to date agreed to these new health pacts, representing over $18.3bn of fresh investment.
Details of the Declined Deal
The funds for Zimbabwe was intended to gone towards "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this collaboration could have provided extraordinary benefits for Zimbabwean communities, particularly the 1.2 million men, women and children presently on antiretroviral therapy via US-supported programmes," the Ambassador added.
However, government spokesperson Nick Mangwana argued the proposed deal was "unequal".
"Our nation was requested to surrender its genetic material and health information over an extended period, with no corresponding assurance of access to any scientific breakthroughs – like new medicines or tests – that could be developed from that shared data," Mangwana explained.
"In essence, our nation would provide the raw materials for scientific discovery without any certainty that the end products would be accessible to our citizens if a future pandemic emerge."
National Interest and International Frameworks
Mangwana further said that the US's withdrawal from the global health body and its pursuit of bilateral health agreements were undermining structures previously established via the global health agency.
Mangwana cited its Pandemic Benefit-Sharing scheme designed to manage potential pandemics.
"This system is intended to ensure that when a nation provides its samples, the benefits – including vaccines and treatments – are shared equitably, not monopolised solely by those with the resources to create them."
Zimbabwe's reservations regarding the US deal "are not meant as opposition to America," he added.
"We welcome further dialogue with our American counterparts on how subsequent collaboration could be structured in a manner that respects the independence and interests of each country."
Health Experts Response
A leading public health body stated it recognised the official position, but suggested that negotiations must proceed given that a large portion of the country's HIV programmes were funded by external financing.
"If technical issues arise, such as those involving data governance or agreement terms, these can frequently be resolved via detailed discussion and negotiated safeguards," the group added.
The situation emphasises the complex challenges between receiving much-needed international aid and safeguarding national sovereignty in an increasingly interconnected world.